[1] WHO. Global Hepatitis Report, 2017. Geneva: World Health Organization, 2017.
[2] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
[3] Liu J, Zhang SK, Wang QM, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016,16(1):80-86.
[4] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209-249.
[5] Chen WQ, ZhengRS, Baade PD, et al. Cancer statistis in China,2015. CA Cancer J Clin. 2016,66(2):115-132.
[6] Allemani C, Matsuda T, Carlo VD, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet,2018,17;391(10125):1023-1075.
[7] Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health, 2020,8(2):e180-e190.
[8] Jang JW, Kin JS, Kim HS, et al. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Clin mol hepatol,2021,27(1):207-218.
[9] Lee. Old hepatitis B virus never dies: It just hides itself within the host genome. Clin Mol Hepatol,2021,27(1):107-109.
[10] 郑传芬,曾惠,王佳,等. 重庆地区黄曲霉毒素暴露与原发性肝癌关联的病例对照研究. 中华预防医学杂志,2017,51(6):539-545.
[11] Zhang WL, He H,Zang MY,et al. Genetic features of aflatoxin associated hepatocellular carcinoma. Gastroenterology,2017,153(1):249-262.e2.
[12] Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018,May 23;38:262-279.
[13] Liu X, Baecker A, Wu M, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population. Int J Cancer,2018,142(8):1560-1567.
[14] Chuang SC,Lee YCA,Wu GJ,et al. Alcohol consumption and liver cancer risk:a meta analysis. Cancer Causes Control,2015,26(9):1205-1231.
[15] Pang YJ, Kartsonaki C, Turnbull L, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people. Hepatology,2018,68(4):1308-1318.
[16] Sohn W, Lee HW, Lee S, et al. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol,2021,27(1):157-174.
[17] Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B:a large cohort study. Gastroenterology.2017,153(4):1006-1017.e5.
[18] Ma X,Yang Y, Li HL,et al. Dietary trace element intake and liver cancer risk: Results from two population- based cohorts in China. Int J Cancer,2017,140(5):1050-1059.
[19] Lok ASF, Mcmahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology,2016,63(1):284-306.
[20] Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol, 2019,70(3):361-370.
[21] Kim JH, Sinn DH,Kang W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology,2017,66(2):335-343.
[22] Kim GAK, Lim YS, Han SB, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut,2018,67(5):945-952.
[23] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int,2017,11(4):317-370.
[24] 贾蓉蓉,霍荣瑞,骆成飘,等.乙型肝炎表面抗原转阴患者发生肝细胞癌危险因素的系统评价. 中国循证医学杂志,2018,18(12):1311-1317.
[25] Kuang XJ, Jia RR, Huo RR,et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat,2018,25(9)1026-1027.
[26] Dave S,Park S, Murad MH,et al.Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatology,2021,73(1):68-78.
[27] Yip TCF, Wong VWS, Chan HLY, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology,2020,158(1):215-225.e6.
[28] Chang TS, Yang YH, Chen WM, et al. Long term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep,2021,11(1):1365.
[29] Liang KH, Hsu CW, Chang ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis,2016,213(6):966-974.
[30] Ren PP, Cao ZJ, Mo RD, et al.Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther,2018,18(10):1085-1094.
[31] Li XK, Zhou DQ, Chi XL, et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial. Hepatol Int,2020,14(6):985-996.
[32] Xing YF, Wei CS,Zhou TR, et al. Efficacy of a Chinese herbal formula on hepatitis B e antigenpositivechronic hepatitis B patients. World J Gastroenterol,2020,26(30):4501-4522. |
